Skip to content

TRAVETANCHE INJECTION

Active
Private limited companyfounded 2005active for 21 yearsOudenakenstraat 25, 1600 Sint-Pieters-Leeuw, BelgiumKBO/BCE: BE 0875.525.265
Summary

TRAVETANCHE INJECTION has been active since 2005 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €586,877 and a net result of €148,022. Equity has been stable since 2018 (±2% per year). Its solvency ranks better than 70% of 34,954 sector peers (NACE 43, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Overview

Official details

Source: KBO
Status
Active since 11-08-2005 Normal situation
Activity
Insulation installation NACE 43230and 1 other
Establishment unit
2.148.678.672 1600 Sint-Pieters-Leeuw, since 28-07-2005
Financial year end
31 December
Peppol
Reachable since 19-06-2025

Board and ownership

Board

Financial position

95 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
< 0.1%
Annual accounts 2025
Gross margin
€558,440
▲ 12.1%
Turnover
≈ €1.4m
estimated
Profit
€148,022
▲ 18.9%
Equity
€586,877
▼ 0.6%
Total assets
€902,350
▲ 8.5%
Employees on 31-12-2025
6
▲ 20.0%
Score breakdownraises riskSector: Specialised construction activities (NACE 43)lowers riskLiquidity: current ratio 2.66, cash €251,373Size: total assets €902,350Equity €586,877 (65.0% of total assets)Show the evidence

Checked score

Score 2025
95 / 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 62% of micro companies in specialised construction (NACE 43)
Financial strength · tick: 2024
Strong
Solvency 90-6
equity 65.0% of total assets
Liquidity 69-13
short-term debt 35.0% · cash 27.9%
Profitability 89+2
return on assets 16.4%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.7% (47,675 companies, NACE 43, micro)
Last 24 months 12-2024: < 0.1% 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: 0.1%▲ +0.1 percentage points vs 05-2025 07-2025: 0.1%● unchanged vs 06-2025highest value 08-2025: < 0.1%▼ -0.1 percentage points vs 07-2025lowest value 09-2025: < 0.1%● unchanged vs 08-2025lowest value 10-2025: < 0.1%● unchanged vs 09-2025lowest value 11-2025: < 0.1%● unchanged vs 10-2025lowest value 12-2025: < 0.1%● unchanged vs 11-2025lowest value 01-2026: < 0.1%● unchanged vs 12-2025lowest value 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: < 0.1%● unchanged vs 07-2026 09-2026: < 0.1%● unchanged vs 08-2026 10-2026: < 0.1%● unchanged vs 09-2026 11-2026: < 0.1%● unchanged vs 10-2026
Credit of up to €55,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 2.66 (3.09 in 2024), above the usual 1.5. Short-term debt is 35% and cash 27.9% of total assets. 35% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 43, micro). It does better than 71% of them on solvency, 68% on liquidity, 75% on profitability and 33% on growth.

The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Five signals.
lowers riskraises riskneutral
lowers risk · Liquidity: current ratio 2.66, cash €251,373
NBB · annual accounts
raises risk · Sector: Specialised construction activities (NACE 43)
KBO
lowers risk · Size: total assets €902,350
Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
lowers risk · Equity €586,877 (65.0% of total assets)
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-06-2026, 32 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
32 days early
2024
30 days early
2023
33 days early
2022
19 days early
2021
30 days late
2020
31 days late
2019
91 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 5 days after the deadline. In the sector (NACE 43), the median for financial year 2024 was 1 day before the deadline, and 43% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 1 July (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
03-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Key points

  • Positive: Higher net result than 95% of companies in specialised constructionsector median €10,221 · 34,941 companies €148,022 View
  • Positive: 8 profitable years in a rowprofit 2025: €148,022 8 years View
  • Positive: Filed on time since financial year 2022accounts within the deadline every year 4 years View

Recent changes

  1. · Gazette deed Capital increase of €7,547 to €26,147Change of role: VERMEULEN Bruno Jean Philippe, from manager to director
  2. · Gazette deed Incorporation
All 13 events

Comparable companies

These companies have the same main activity as TRAVETANCHE INJECTION: insulation installation (NACE 43230). They are comparable in size and age: total assets between €717,000 and €1.3m, founded between 2002 and 2007.

CompanyTotal assetsGross margin
TRAVETANCHE INJECTION Sint-Pieters-Leeuw€0.9m€0.6m
ISOLPRO Lubbeek€1.0m€0.6m
DETHA DOORS Roosdaal€0.9m€0.6m
Gevelconcept Waelkens Deerlijk€0.9m€0.4m
KONOS AIR Zaventem€1.3m€0.7m
ISOMONT Antwerpen€0.7m€0.5m
ELASTOFLEX PROJECTS Hasselt€1.1m€0.8m
Full comparison

Key facts about TRAVETANCHE INJECTION

What is the company number of TRAVETANCHE INJECTION?
The company number of TRAVETANCHE INJECTION is 0875.525.265. The VAT number is the same number with BE in front: BE 0875.525.265.
Where is TRAVETANCHE INJECTION based?
The registered office is at Oudenakenstraat 25, 1600 Sint-Pieters-Leeuw.Company details
What does TRAVETANCHE INJECTION do?
According to the KBO register, the main activity is insulation installation (NACE 43230).
What is the legal form of TRAVETANCHE INJECTION?
The legal form of TRAVETANCHE INJECTION is Private limited company (BV).
When was TRAVETANCHE INJECTION founded?
TRAVETANCHE INJECTION was founded on 11-08-2005.
Is TRAVETANCHE INJECTION still active?
Yes, TRAVETANCHE INJECTION is an active enterprise in the KBO register.
How many employees does TRAVETANCHE INJECTION have?
TRAVETANCHE INJECTION had an average of 6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of TRAVETANCHE INJECTION?
The turnover in financial year 2025 is ≈ €1.4m. This figure is estimated from the gross margin of €558,440 and 32 comparable companies (NACE 432). It probably lies between €1.1m and €1.8m.
Is TRAVETANCHE INJECTION profitable?
In financial year 2025, TRAVETANCHE INJECTION made a profit of €148,022.
Where can I find the annual accounts of TRAVETANCHE INJECTION?
TRAVETANCHE INJECTION filed 20 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of TRAVETANCHE INJECTION due?
TRAVETANCHE INJECTION must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.